Enrolling by invitationNot applicableNCT05872022
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
Studying Hydatidiform mole
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novo Nordisk A/S
- Principal Investigator
- Clinical Transparency (dept. 2834).Novo Nordisk A/S
- Intervention
- No Intervention(other)
- Eligibility
- 15-50 years · FEMALE
- Timeline
- 2023 – 2032
Study locations (3)
- Novo Nordisk Investigational Site, Princeton, New Jersey, United States
- Novo Nordisk Investigational Site, Madrid, Spain
- Novo Nordisk Investigational Site, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05872022 on ClinicalTrials.govOther trials for Hydatidiform mole
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06113237Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During PregnancyJazz Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT05516810The Accuracy of Ultrasound Diagnosis of Hydatidiform MolesKing's College Hospital NHS Trust
- RECRUITINGNANCT03785574Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung NoduleWomen's Hospital School Of Medicine Zhejiang University
- ACTIVE NOT RECRUITINGNCT01008501Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform MolesBaylor College of Medicine